Herein, we examined insulin resistance (IR), insulin sensitivity (IS), beta cell activity, and glucose metabolism in subjects with antisocial personality disorder (ASPD), and whether the serotonin 2B (5-HT2B) receptor and testosterone have a role in energy metabolism. A cohort of subjects belonging to a founder population that included 98 ASPD males, aged 25e30, was divided into groups based on the presence of a heterozygous 5-HT2B receptor loss-of-function gene mutation (HTR2B Q20*; n ¼ 9) or not (n ¼ 89). Serum glucose and insulin levels were measured in a 5 h oral glucose tolerance test (75 g) and indices describing IR, IS, and beta cell activity were calculated. Body mass index (BMI) was also determined. Concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid were measured in cerebrospinal fluid, and testosterone levels from serum. An IR-like state comprising high IR, low IS, and high beta cell activity indices was observed among ASPD subjects without the HTR2B Q20* allele. By contrast, being an ASPD HTR2B Q20* carrier appeared to be preventive of these pathophysiologies. The HTR2B Q20* allele and testosterone predicted lower BMI independently, but an interaction between HTR2B Q20* and testosterone lead to increased insulin sensitivity among HTR2B Q20* carriers with low testosterone levels. The HTR2B Q20* allele also predicted reduced beta cell activity and enhanced glucose metabolism. Reduced 5-HT2B receptor function at low or normal testosterone levels may be protective of obesity. Results were observed among Finnish males having an antisocial personality disorder, which limits the generality.
Introduction
Comorbidities of psychiatric and metabolic disorders are frequent. For example, more than 25% of individuals diagnosed with diabetes also suffer from depression (Lustman and Clouse, 2005) . The combined impact of metabolic and psychiatric disorders decreases daily executive performance and quality of life, causes severe organ complications, and increases mortality, which support a rationale to further examine metabolic pathophysiologies associated with distinct psychiatric disorders. ASPD is a psychiatric disorder, with a prevalence of 1% (Lenzenweger et al., 2007) , which is linked to an inherently impulsive lifestyle that puts ASPD patients at risk for metabolic disorders because of challenges in maintaining a healthy diet and physical exercise. A Finnish violent offender population saturated with ASPD individuals has been shown to exhibit elevated basal insulin levels (Ojala et al., 2015) .
In addition to the clinical hypothesis that patients with ASPD are at an increased risk for insulin-related pathophysiologies, we also hypothesized that the serotonergic pathway could alter insulin secretion and glucose homeostasis. Indeed, preliminary evidence that was mostly obtained from animal study settings suggest that serotonin (5-HT) is involved in the control of islet function and links to insulin resistance (IR) (Bennet et al., 2015; Saunders et al., 2014) . Moreover, some studies imply that functional silencing of the serotonin 2B (5-HT2B) receptor may have protective effects on risk for IR and type 2 diabetes (T2D) because the function of the receptor seems to alter islet function and glucose homeostasis (Bennet et al., 2016; Kim et al., 2010 Kim et al., , 2015 Tikkanen et al., 2016; Yamada et al., 1998) . However, the role of the G q -coupled serotonin 5-HT2B receptor in human somatic health is poorly characterized, but in psychiatric research studies the 5-HT2B receptor has been recently shown to exert the following tangible effects on human behavior and psychiatric symptoms: increased impulsive behavior, alcoholrelated problem-behavior, emotional dysregulation, mood disorders, and anxiety (Bevilacqua et al., 2010; Tikkanen et al., 2015) .
To examine the effects of the serotonergic pathway, we studied heterozygous carriers of a 5-HT2B receptor gene mutation (HTR2B Q20*) detected in a Finnish young founder population (Bevilacqua et al., 2010) . HTR2B Q20* is a point-mutation of the 5-HT2B receptor gene, which is located at 2q36-q37. The mutation results in interrupted expression of the 5-HT2B receptor in lymphoblastoid cells, which results in a 50% reduction of the expression of the receptor protein in heterozygous individuals (Bevilacqua et al., 2010) . The prevalence of the hereditary HTR2B Q20* is relatively high (2.2%) in the Finnish general population. Testosterone was included in analyzes because testosterone levels has been suggested to be elevated in HTR2B knockout mice and heterozygous HTR2B Q20* carriers in comparison to carriers of the wild type allele (Bevilacqua et al., 2010) . Also, reduced testosterone levels have been associated with IR, T2D and obesity (Haffner et al., 1994; Jones, 2010) .
Material and methods

Subjects and subgroups
Subjects were obtained from a genotyped cohort that included Finnish alcoholic violent offenders, their relatives, along with healthy controls who were recruited by newspaper advertisements; the cohort included a total of 875 subjects. This cohort was collected to detect biological risk factors for psychiatric disorders and impulsive behaviors. All subjects diagnosed with ASPD that had participated in an oral glucose tolerance test (OGTT) were included without pre-selection, resulting in a total of 98 subjects, all males, who were separated for comparison into the following two groups: heterozygote HTR2B Q20* allele carriers (n ¼ 9) and subjects homozygous for the wild-type HTR2B Q20 allele (n ¼ 89). The genotyping procedure has been previously described in detail by Bevilacqua et al. (2010) . Genetic and molecular analyzes were performed at the Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, NIH (Bethesda, MD, USA).
Laboratory tests
Serum levels of glucose, insulin, and testosterone, and gammaglutamyl transferase were measured after fasting overnight. Insulin was analyzed using a radioimmunoassay method and quantified in antibody-coated test tubes (Count-A-Count, Diagnostic Products Corporation, Los Angeles, CA, USA). Between-assay variation for insulin was 4.6% at 215 pmol/l. All samples were assayed in duplicate. When results of duplicate measurements showed discrepancies of more than 5%, samples were reanalyzed (Virkkunen et al., 1994) . For clinical convenience, insulin levels are reported as mU/L. None of the participants had previously used antidepressants or antipsychotics within the two weeks prior to the laboratory tests; lack of drug use status was verified using urine tests. All subjects ate the same food and were not allowed to exercise 24-h prior to measurements. OGTT was administered after 12-to 16-h fasting overnight. At 8 a.m., participants drank a solution containing 75 g glucose (Leiras, Turku, Finland), which was ingested as quickly as possible. From an antecubital vein, nine blood samples (15 mL each) were collected during the 5 h test. For the first 2 h of the test, subjects rested in bed. Thereafter, they were allowed to move about the ward, but resting was encouraged. Blood glucose concentrations were determined enzymatically. Blood samples were stored in tubes that contained sodium fluoride.
Levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured from cerebrospinal fluid (CSF) that was obtained by lumbar puncture. A total of 12 mL CSF was collected and 5-HIAA concentrations were analyzed by liquid chromatography and electrochemical detection methods. Prior to puncture between 8 and 9 a.m. the subjects had only been allowed to drink water after 8 p.m. the night before. Moreover, they had eaten the same food and were not allowed to exercise 24 h prior the puncture. No subjects had used a psychoactive medication, such as selective serotonin reuptake inhibitors, within the previous two weeks, which was confirmed by urine tests.
2.3. Measurements of glucose levels, insulin resistance, insulin sensitivity, and beta cell activity WHO, (2006) definitions for normal and pathophysiological glucose levels were used. Normal fasting glucose levels were defined as 3.9e6.0 mmol/L, impaired fasting glucose tolerance (IFG) was defined as 6.1e6.9 mmol/L, and diabetes was defined as !7.0 mmol/L. The following glucose reference values at 120 min measurements in the OGTT were used to define impaired glucose tolerance (IGT) and diabetes, respectively: !7.8 and 11.0 mmol/L and !11.1. Additionally, IR, IS, and beta cell activity were calculated using the homeostasis model assessment calculator (Levy et al., 1998) (https://www.dtu.ox.ac.uk/homacalculator, accessed 02.03.16), which utilizes fasting glucose and fasting insulin values. Normal reference values for HOMA2 IR, IS, and beta cell activity are 1.0, 100%, and 100%, respectively. Furthermore, IR and IS were assessed based on the whole body insulin sensitivity index (WBISI) (Matsuda and DeFronzo, 1999) calculated from measurements obtained from the OGTT utilizing glucose and insulin values at baseline, and at 30, 60, 90, and 120 min (http://mmatsuda.diabetes-smc. jp/MIndex.html, accessed 02.04.16). A WBISI value of 2.5 denoted pathological whole body insulin resistance.
Area under the curve (AUC)
AUC values were calculated using the trapezoidal method (Purves, 1992) representing the "average curve" because it has been suggested that subtle biological variance might not be detected when presenting the "curve of averages" alone (Allison et al., 1995; Matthews et al., 1990) . When the golden standard 2 h AUC was used for calculations of the AUC value, it was subtracted from the baseline value for each subject. Then, mean values were compared between groups.
Fat percentage
Fat percentages were measured using a four-terminal portable impedance analyzer (BIA 101, RJL Systems, Detroit MI, USA), which is a bioelectrical impedance technique that measures total body water, fat-free body mass, and, consequently, fat percentage. Measurements were performed as described previously by Lukaski et al. (1985) .
Psychiatric disorders
All subjects were examined based on the DSM-III-R semistructured interview to detect psychiatric disorders (American Psychiatric Association, 1987; Spitzer et al., 1988) . Experienced psychiatrists conducted the interviews and two research psychiatrists rated the interview data blindly under the supervision of a senior research psychiatrist. Inter-rater reliability was high, and the senior psychiatrist resolved any discrepancies.
Statistical analyzes
A normal distribution of variables was tested using the KolmogoroveSmirnov test. Asymmetric variable variances of mean values were tested using the ManneWhitney U test. Comparisons of mean values for normally distributed variables were performed using two-tailed independent samples t-test letting the Levene's test of equality of variances determine the appropriate p-value. Multiple linear regression analyses were conducted to detect predictors of the main metabolic dependents. The SPSS 22.0 software package (SPSS Inc., Chicago, IL, USA) was used for all calculations with a significance level set at the 95% CI.
Ethics
Written informed consent was obtained from each participant. The study protocol was approved by the Institutional Review Boards of the Department of Psychiatry at the University of Helsinki and the Helsinki University Central Hospital.
Results
Measurements of glucose, insulin, IR, IS, beta cell activity, AUCs, and testosterone
No subjects exhibited pathological fasting or OGTT glucose values (i.e., impaired fasting glucose, IGT, or diabetes). However, ASPD subjects without HTR2B Q20* had increased IR, decreased IS, and high beta cell activity values; a significant difference in AUCs was observed between the groups. Table 1 and Fig. 1 display the most notable differences between groups. Testosterone levels were equal between groups.
Effects of metabolic predictors and age on BMI, IR, IS and beta cell activity
The multiple regression analyses were adjusted for age, BMI (not in the model where BMI was entered as the dependent) and gamma-glutamyl transferase. They detected both main effects and an interaction, which are presented in Table 2 and Fig. 2 . The main results are discussed in the Discussion section, but it is notable that also age and BMI seemed to predict outcomes in a consistent manner.
Psychiatric disorders
All subjects fulfilled the criteria for ASPD. Borderline personality disorder was somewhat frequent in both groups, as it was present in 33% of HTR2B Q20* carriers and 43% of subjects without the mutation. All subjects without HTR2B Q20* fulfilled the criteria for a diagnosis of alcohol dependence, whereas alcohol dependence criteria were fulfilled by 89% of subjects among HTR2B Q20* carriers as one subject received a diagnosis of alcohol abuse.
Discussion
Our main finding in the larger cohort of ASPD subjects without HTR2B Q20* was that they exhibited an IR-like state characterized by high IR, low IS, and high beta cell activity indices, even though they were non-obese and normoglycemic. IGT was not observed during the OGTT. Thus, it is notable that the glucose levels at the 2 h measurements in the OGTT among ASPD subjects without HTR2B Q20* were not sufficiently aberrant to claim clinically diagnostic IR or T2D. However, the combination of an IR-like state and normoglycemia that we observed might be interpreted as a constellation of elevated insulin secretion relative to normoglycemia, which has recently been reported to have a distinct genetic background in patients with diabetes (Dimas et al., 2014) . On the other hand, the IR-like findings may be a regular milestone on the risk path to develop T2D. The ASPD subjects without HTR2B Q20* were nonobese and had a low fat percentage, which also could have a distinct genetic basis. Approximately 100 BMI-associated single nucleotide polymorphisms have been identified and determined to explain a small amount of BMI variation (2.7%) (Konttinen et al., 2015) . By contrast, genome-wide estimates have suggested that common genetic variation accounts for 20e30% of the variance in BMI (Llewellyn et al., 2013; Locke et al., 2015) . We may speculate that having a higher amount of brown adipose tissue (BAT) allows glucose to be actively cleared from circulation, making it a protective physiological feature that guards against weight gain (Hanssen et al., 2015; Harms and Seale, 2013 ), but we did not measure BAT. Peripheral 5-HT synthesis has been recently shown to regulate BAT thermogenesis along with associated energy expenditure (Crane et al., 2015) , which could partly explain the normal BMI among ASPD subjects without the HTR2B Q20* allele as ASPD has been associated with aberrant 5-HT metabolite levels in the CSF (Virkkunen et al., 1994) . Although the mechanisms are unclear, the normoglycemia observed could also be explained by that ASPD subjects have been found to have a tendency towards functionally low glucose levels and exhibit low glycogen formation (Virkkunen et al., 2007 (Virkkunen et al., , 2009 .
Being a HTR2B Q20* carrier appeared to be protective against the IR, IS, and beta cell activity pathophysiologies. The glucose metabolism was enhanced and insulin secretion were also lower among HTR2B Q20* carriers. These findings are in accord with earlier reports of the role of the 5-HT2B receptor in regulating insulin secretion and glucose homeostasis, which mainly analyzed knockout animals (Bennet et al., 2016; Kim et al., 2010 Kim et al., , 2015 Yamada et al., 1998) but suggest that similar effects may also appear in humans. It would be unusual that one gene could exhibit such a large effect on the phenotype. However, in this present study, such a scenario could be possible because it included heterozygous HTR2B Q20* carriers with a 50% reduction in 5-HT2B receptor abundance and all subjects belonged to a young founder population, which has been estimated to increase the power to detect the effects of alleles that are present at low-frequencies (0.5e5%) on complex disorders (Lim et al., 2014) . Our observation that the levels of the 5-HT metabolite 5-HIAA in the CSF showed no difference between groups also suggests that the effects that we observed may have been caused by altered function of the 5-HT2B receptor rather than effects resulting from variance in the physiological supply of serotonin. Additionally, the experiments performed by Bennet et al. (2016) suggest that the effects of the 5-HT2B receptor on insulin secretion involve both exocytotic and intracellular mechanisms. Also, they provided evidence that the 5-HT2B receptor alters Ca 2þ influx and the rate of mitochondrial oxidative consumption. Such profound biological variation may indicate that effects on phenotype could be detected. Additional underlying causes other than a direct effect of HTR2B Q20* on islet function and glucose homeostasis are currently speculative, although several likely possibilities exist. For example, our findings could be partially explained by geneegene interactions. The 5-HT1D receptor (formerly known as 5-HTR1D a ) gene, HTR1D, is of particular interest because a polymorphism has been detected in the coding region of this gene (Ozaki et al., 1995) and its expression level has been potentially linked to defective insulin secretion in human T2D (Bennet et al., 2015) . The 5-HT1B receptor (formerly known as 5-HT1D ß ) is also of interest because the protein is 64% identical and nearly pharmacologically indistinguishable from the 5-HT1D receptor protein . Furthermore, a highly bioactive intracellular proteolytic enzyme (26 S proteasome non-ATP regulatory subunit 1) gene (PSMD1) is located at the same locus (chr2:231,056,-864e231,172,827; GRCh38/hg38) as HTR2B, completely overlapping it, but on the opposite strand (PSMD1 is on þ strand, whereas HTR2B is on -). The minor allele of rs79874540 A(T) enables the stop codon composition of HTR2B Q20*, whereas in PSMD1, rs79874540 is an intronic variant and does not have a known effect on the stability of the protein. However, one of the gene transcripts (ENST00000431051 [þ] ) is a target of nonsense-mediated RNA decay (NMD), whereby the alternate allele might play a role. Although unlikely, it is possible that PSMD1-dependent functions are also aberrant among HTR2B Q20* carriers. PSMD1 has been shown to alter the risk for some CNS and cardiac diseases, such as Parkinson's disease and cardiomyopathies (Chung et al., 2001; Predmore et al., 2010) , but it has not yet been established to have a role in either islet function or glucose homeostasis. Moreover, complex neuronal interactions are likely to occur in the process that regulates the secretion of islet hormones. Some evidence suggests that both 5-HT and dopamine can alter IR in metabolic disorders (Konner and Bruning, 2012) . More specifically, preliminary evidence suggests that high dopaminergic activity in the pancreas can inhibit glucose-stimulated insulin secretion (GSIS) and alter beta cell Ca 2þ influx via dopamine receptor D3 (Ustione and Piston, 2012). Matsuda and DeFronzo (1999) , based on glucose and insulin levels obtained from OGTT. c Whole Body Insulin Sensitivity (WBISI). Fig. 1 . Serum glucose and insulin mean value curves obtained from an oral glucose tolerance test among carriers of a loss-of-function 5-HT2B receptor gene mutation (HTR2B Q20*) versus subjects without the mutation (HTR2B Q20) in a sample comprising males diagnosed with antisocial personality disorder (ASPD). Functions show the "curve of averages", and the vertically striped areas show the significant differences (p < 0.01) in the area under the curve (AUC 0e120min ) calculated using the trapezoidal method to describe the "average curve". * ¼ p < 0.05, ** ¼ p < 0.01.
Table 2
The effects of a HTR2B stop codon (HTR2B Q20*) and testosterone on metabolic parameters in a cohort of males diagnosed with antisocial personality disorder. GGT ¼ Gammaglutamyl transferase. R 2 ¼ R squared explanatory power of the model. Results that are printed in bold font are significant at the 95% CI level. Results extracted from the regression analyzes partly explain the mean value differences found in energy metabolism parameters between the comparison groups. The HTR2B Q20* allele predicted lower BMI, reduced beta cell activity, and reduced glucose excursion. However, testosterone also predicted low BMI, independently from the effect of the HTR2B Q20* allele. This main effect of testosterone on BMI is in line with earlier research (Haffner et al., 1994; Jones, 2010) . Interestingly, an interaction occurred between HTR2B Q20* and testosterone to predict insulin sensitivity in a model that explained 19% of the variance (b ¼ À1.10, SE ¼ 0.44, t ¼ À2.47, p ¼ 0.016, R 2 ¼ 0.19). This interaction suggests that the effect of testosterone is reversed among HTR2B Q20* carriers; they have an improved insulin sensitivity in the presence of low testosterone levels whereas subjects without this 5-HTR2B mutation have reduced insulin sensitivity in the same low testosterone environment. This effect may be driven by that HTR2B Q20* predicted reduced glucose excursion and reduced beta cell activity as the WBISI measures variation in both glucose and insulin levels after oral glucose challenge. Moreover, this interaction represent a potential causal mechanism for that HTR2B Q20* predicted reduced BMI in the model that accounted for the effect of testosterone. An interaction between the functioning of the 5-HT2B receptor and testosterone has not been reported in earlier research. The main effect of the HTR2B Q20* allele on BMI in humans is also a preliminary finding. However, it seems comprehensive as the serotonergic pathway has been linked to IR in animal settings (Bennet et al., 2015 (Bennet et al., , 2016 Kim et al., 2015; Saunders et al., 2014) . Also, high-rate catabolism of monoamines, including 5-HT, has been associated with low BMI in humans (Ducci et al., 2006) . In theory, the interaction between HTR2B Q20* and testosterone would put HTR2B Q20* carriers with high testosterone levels at risk for reduced insulin sensitivity as compared to carriers of the wild-type allele. The regression lines crossed approximately at the testosterone level 27 nmol/L in our sample, which left 10% of the total sample above this pivotal point. Although our results are preliminary and correlative, the results suggest that the effect of testosterone on energy metabolism may partly be dependent of serotonergic mechanisms similar to the relationship between serotonin and insulin-related metabolism (Bennet et al., 2016; Tikkanen et al., 2016) . Our results may describe a biochemical physiologic mechanism as the sample was homogeneous and likely exhibited only small variance in behavior. However, to understand the meaning and mechanisms of the relationships between energy metabolism, serotonergic pathway, and testosterone, GSIS laboratory settings should be conducted where the 5-HTR2B could be silenced and the testosterone environment could be altered simultaneously. Alcohol consumption should be considered in our interpretation of the results because it has been reported to be high in a Finnish violent offender population with a high prevalence of ASPD (Tikkanen et al., 2009) . Persistently abundant alcohol consumption is associated with an increased risk of chronic pancreatitis (Ammann, 2001) , which can lead to irreversible islet destruction and, consequently, decreased insulin secretion. In this context, insulin responses to oral glucose load are severely impaired and result in overt hyperglycemia during OGTTda pattern that we did not observe in any of our subjects. By contrast, modest, but regular alcohol consumption has been shown to be a protective factor against T2D (Carlsson et al., 2003) . We included gamma-glutamyl transferase levels in the regression analyzes to decrease the possible bias of variance in alcohol consumption. However, all subjects had homogeneously a diagnosis of an alcohol use disorder, which is typical conjunct to ASPD. On the other hand, subjects had abstained for a four to eight week period prior to the tests because they were subjected to a court-ordered mandatory inpatient forensic mental status examination.
The small number of HTR2B Q20* subjects limits the power of our statistical analyzes. In addition to type I errors, type II errors may have occurred as the multiple linear regression analyzes are robust. Moreover, comparisons of results from human heterozygote studies with those of homozygous knockout animals should be cautious. However, the 50% reduction of 5-HTR2B receptor protein levels in the HTR2B Q20* subjects should lend support to hypothesize that comparisons to animal knockout studies could be made. We did not analyze environmental factors, which increases the risk of obtaining spurious results. E.g., dietary habits were not controlled for, but HTR2B Q20* has been linked to impulsive behaviors (Bevilacqua et al., 2010; Tikkanen et al., 2015) , which would likely bias results in the opposite direction assuming that impulsive behavior decreases dietary control. A strength of our study was that the cohort was homogenous regarding ASPD diagnosis.
In future studies, the putative role of the 5-HT2B receptor in IR and T2D should be examined in different patient cohorts and risk groups. The importance of examining the effects of 5-HT receptors in diverse populations is emphasized by the finding that the effects of 5-HT pathways on insulin secretion appear to differ in nondiabetics and diabetics for unknown reasons. Evidence for this was provided by Bennet et al. (2015) who showed that (i) HTR1D and HTR2A are overexpressed in the islets of diabetic, but not nondiabetic donors, (ii) 5-HT1D receptor inhibits, whereas 5-HT2A receptor potentiates GSIS in non-diabetic, but not in diabetic islets, and (iii) diabetic islets lose sensitivity to the inhibitory effects of 5-HT on GSIS.
Together, our findings suggest that ASPD may be a risk group for insulin-related metabolic pathophysiology, which could be important to account for in clinical practice as IR, IS and beta cell activity indices has been shown to predict obesity, T2D, and cardiovascular diseases (Nolan and Faerch, 2012) . Being an ASPD HTR2B Q20* carrier appeared to normalize insulin-related pathophysiologies, which implies that silencing the 5-HT2B receptor may have protective effects on metabolic disorders. Results were observed among Finnish males having an antisocial personality disorder, which limits the generality.
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